Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex
Abstract Background Tuberous sclerosis complex (TSC) is a rare autosomal dominant disorder forming hamartomas throughout the body. Facial angiofibromas (FAs) occur in 75% of TSC patients, which are often enlarged, impairing the appearance of the face, and reducing the patient’s quality of life (QOL)...
Main Authors: | Takashi Hatano, Yuki Ohno, Yu Imai, Jun Moritake, Katsuhisa Endo, Mayumi Tamari, Shin Egawa |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-020-01417-5 |
Similar Items
-
Topical sirolimus in facial angiofibroma
by: Prachi Chetankumar Gajjar, et al.
Published: (2018-01-01) -
Facial angiofibromas of tuberous sclerosis treated with topical sirolimus in an Indian patient
by: Resham J Vasani
Published: (2015-01-01) -
Topical rapamycin (sirolimus) for facial angiofibromas
by: Bhushan Madke
Published: (2013-01-01) -
Early Sirolimus Gel Treatment May Diminish Angiofibromas and Prevent Angiofibroma Recurrence in Children With Tuberous Sclerosis Complex
by: Tohru Okanishi, et al.
Published: (2020-01-01) -
Use of topical rapamycin in facial angiofibromas in Indian skin type
by: Vishalakshi Viswanath, et al.
Published: (2016-01-01)